- Condition: Gram-Negative Bacterial Infections
Interventions: Drug: Beta-Lactams; Drug: Beta-Lactams
Sponsors: National Taiwan University Hospital; National Taiwan University Hospital
Recruiting - verified February 2012 - Conditions: HIV Infection; Tuberculosis
Interventions: Drug: Lopinavir/Ritonavir; Drug: Lopinavir/Ritonavir; Drug: Raltegravir; Drug: Isoniazid; Drug: Pyridoxine; Drug: Pyrazinamide; Drug: Ethambutol; Drug: Rifabutin; Drug: Rifampin
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified May 2012 - Condition: Tuberculosis
Intervention:
Sponsors: Singapore General Hospital; Singapore General Hospital
Recruiting - verified May 2012 - Condition: Pulmonary Tuberculosis
Interventions: Biological: ID93 + GLA-SE; Biological: ID93 alone
Sponsors: Infectious Disease Research Institute; Infectious Disease Research Institute; Aeras Global TB Vaccine Foundation; Bill and Melinda Gates Foundation; Paul G. Allen Family Foundation
Not yet recruiting - verified May 2012 - Condition: Clostridium Difficile Infection
Interventions: Drug: CB-183,315; Drug: oral vancomycin
Sponsors: Cubist Pharmaceuticals; Cubist Pharmaceuticals
Recruiting - verified May 2012 - Condition: Clostridium Difficile Infection
Interventions: Drug: CB-183,315; Drug: oral vancomycin
Sponsors: Cubist Pharmaceuticals; Cubist Pharmaceuticals
Recruiting - verified May 2012 - Condition: Cystic Fibrosis
Interventions: Drug: Inhaled Vancomycin; Drug: Placebo (Sterile Water); Drug: Rifampin; Drug: Trimethoprim/Sulfamethoxazole (TMP/SMX); Drug: Doxycycline; Drug: Mupirocin Nasal Ointment; Drug: 4% chlorhexidine gluconate liquid skin cleanser
Sponsors: Johns Hopkins University; Michael Boyle; Case Western Reserve University; Cystic Fibrosis Foundation
Not yet recruiting - verified May 2012 - Condition: Skin Infection
Intervention: Drug: CG400549
Sponsors: CrystalGenomics, Inc.; CrystalGenomics, Inc.
Not yet recruiting - verified May 2012 - Condition: Helicobacter Pylori Infection
Interventions: Dietary Supplement: Lactobacillus reuteri; Dietary Supplement: Placebo
Sponsors: Zagazig University; Zagazig University; BioGaia AB
Not yet recruiting - verified May 2012 - Condition: Bordetella Pertussis Infection
Interventions: Procedure: Blood collection; Other: Data collection
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified May 2012 - Condition: Staphylococcus Aureus
Interventions: Drug: XF-73 in 2% gel; Other: Placebo in 4% gel; Drug: XF-73 in 4% gel
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified May 2012 - Condition: Uncomplicated Urogenital Gonorrhea
Intervention: Drug: solithromycin
Sponsors: Cempra Pharmaceuticals; Cempra Pharmaceuticals
Recruiting - verified May 2012 - Condition: Tuberculosis
Interventions: Drug: Rifampicin; Drug: Isoniazid; Drug: Pyrazinamide; Drug: Ethambutol; Drug: Moxifloxacin
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified April 2012 - Conditions: Neurological Disorders; Cerebral Malaria; Bacterial Meningitis; Central Nervous System Tuberculosis; Neurosyphilis; Cryptococcal Meningitis
Interventions: Device: Immunochromatographic HAT tests (DSD); Device: Card Agglutination Trypanosoma Test; Device: TB POC Nucleic Acid Amplification Test (Molbio Diagnostics); Device: TB 3-marker RDT (Tulip diagnostics); Device: Cryptococcal Antigen Lateral Flow Assay (Immy)
Sponsors: Institute of Tropical Medicine, Belgium; Institute of Tropical Medicine, Belgium; Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo; University Hospital, Geneva
Not yet recruiting - verified April 2012 - Condition: Cholera
Interventions: Biological: PXVX0200; Biological: Placebo
Sponsors: PaxVax, Inc.; PaxVax, Inc.
Not yet recruiting - verified April 2012 - Condition: Multi-drug Resistant Tuberculosis
Interventions: Drug: TMC207; Drug: Placebo; Drug: TMC207; Drug: TMC207
Sponsors: Janssen Infectious Diseases BVBA; Janssen Infectious Diseases BVBA
Not yet recruiting - verified May 2012 - Condition: Tuberculosis
Intervention:
Sponsors: Cepheid; Cepheid; AIDS Clinical Trials Group; Centers for Disease Control and Prevention
Recruiting - verified April 2012 - Condition: Tuberculosis
Intervention:
Sponsors: Research Center Borstel; Research Center Borstel; German Cancer Research Center
Recruiting - verified April 2012 - Conditions: Catheter-related Bloodstream Infection.; Bacteremia.
Interventions: Drug: Administration of vancomycin in antibiotic lock solution; Drug: Administration of teicoplanin in antibiotic lock solution; Drug: Administration of linezolid in antibiotic lock solution; Drug: Administration of daptomycin in antibiotic lock solution; Drug: Administration of tigecycline in antibiotic lock solution
Sponsors: Instituto Cientifico y Tecnologico de Navarra, Universidad de Navarra; Instituto Cientifico y Tecnologico de Navarra, Universidad de Navarra; University of Navarrra Hospital (Clinica Universitaria)
Not yet recruiting - verified May 2012 - Condition: Bacterial Infections
Intervention: Other: Antibiotic stewardship audit-and-feedback to prescribers of patients receiving 3rd or 10th day of targeted broadspectrum antibiotics
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre; Ontario Ministry of Health and Long Term Care
Recruiting - verified April 2012 - Conditions: Diphtheria,; Tetanus and Pertussis
Intervention:
Sponsors: Sanofi Pasteur MSD; Sanofi Pasteur MSD; Oxon Epidemiology/ Chiltern; Dr. José Garcia Sicilia-López; Dr. Francisco Giménez
Recruiting - verified April 2012 - Conditions: Meningitis; Meningococcal Disease; Septicaemia
Interventions: Biological: MenACWY-CRM conjugate vaccine (Menveo, Novartis); Biological: MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis); Biological: MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis); Biological: 1/5th dose MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)
Sponsors: University of Oxford; University of Oxford
Not yet recruiting - verified May 2012 - Condition: Pulmonary Tuberculosis
Interventions: Drug: Active Sodium Phenylbutyrate and active cholecalciferol; Drug: Placebo Sodium Phenylbutyrate plus active cholecalciferol; Drug: Active Sodium Phenylbutyrate and placebo cholecalciferol; Drug: Placebo Sodium Phenylbutyrate plus placebo cholecalciferol
Sponsors: International Centre for Diarrhoeal Disease Research, Bangladesh; International Centre for Diarrhoeal Disease Research, Bangladesh; Dept. of medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden; National Tuberculosis Reference Laboratory, National Institute of Diseases of Chest and Hospital (NIDCH), Dhaka, Bangladesh; Biology Institute, University of Iceland, Sturlugata 7, 101 Reykjavik
Recruiting - verified April 2012 - Condition: Tuberculosis
Intervention:
Sponsors: Research Center Borstel; Research Center Borstel; Alere Technologies GmbH
Recruiting - verified April 2012 - Conditions: HIV; Tuberculosis
Intervention: Other: Cellular Phone Text Message Formats
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Mbarara University of Science and Technology; John E. Fogarty International Center (FIC); Harvard Global Health Institute
Not yet recruiting - verified April 2012 - Condition: Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
Interventions: Drug: 10RAC+acetylcystein; Drug: 10RAC+metronidazole
Sponsors: Buddhist Tzu Chi General Hospital; Buddhist Tzu Chi General Hospital
Recruiting - verified April 2012 - Condition: Cholera
Interventions: Biological: Shanchol™, oral cholera vaccine; Biological: Shanchol™, killed, whole cell, bivalent, oral cholera vaccine; Other: no intervention
Sponsors: International Vaccine Institute; Sachin Desai; National Institute of Cholera and Enteric Diseases, India; Indian Council of Medical Research; SHANTHA BIOTECHNICS LTD
Recruiting - verified May 2012 - Condition: Pneumonia Due to Staphylococcus Aureus
Interventions: Drug: KBSA301; Drug: Placebo
Sponsors: Kenta Biotech Ltd; Kenta Biotech Ltd
Recruiting - verified May 2012 - Condition: Tuberculosis
Intervention: Drug: Rifapentine (RPT)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified May 2012 - Conditions: Haemophilus Influenzae Type b Diseases; Diphtheria; Poliomyelitis; Pertussis; Tetanus
Intervention: Biological: Infanrix-IPV+HibTM
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified April 2012 - Condition: Pneumococcal Infections
Intervention: Biological: Prevnar13 (manufactured by Pfizer)
Sponsors: Agence de Médecine Préventive, France; Agence de Médecine Préventive, France
Not yet recruiting - verified April 2012 - Condition: Latent Tuberculosis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified November 2011 - Condition: Bacterial Conjunctivitis
Interventions: Drug: Moxifloxacin Ophthalmic Solution, 0.5%; Drug: Ofloxacin Ophthalmic Solution, 0.3%
Sponsors: Alcon Research; Alcon Research
Recruiting - verified May 2012 - Condition: Diarrhoea, Clostridium Difficile
Intervention: Drug: Calcium Aluminosilicate Anti-Diarrheal (CASAD)
Sponsors: Salient Pharmaceuticals Incorporated; Salient Pharmaceuticals Incorporated; Scott and White Hospital & Clinic; Texas A&M University
Recruiting - verified April 2012 - Conditions: cUTI; Complicated Urinary Tract Infection; Acute Pyelonephritis
Interventions: Drug: CAZ-AVI; Drug: Doripenem
Sponsors: AstraZeneca; AstraZeneca; Cerexa, Inc.
Not yet recruiting - verified May 2012 - Conditions: Poliomyelitis; Pertussis; Diphtheria; Tetanus
Intervention: Other: Infanrix-IPV data collection
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified May 2012 - Condition: Helicobacter Pylori Infection
Interventions: Drug: RA5-RACM7; Drug: RA3-RACM7; Drug: RA7-RACM7
Sponsors: Buddhist Tzu Chi General Hospital; Buddhist Tzu Chi General Hospital; Kaohsiung Medical University
Recruiting - verified April 2012 - Condition: Tuberculosis
Interventions: Drug: PA-824; Drug: Efavirenz (EFV); Drug: Lopinavir/Ritonavir (LPV/r); Drug: Rifampin (RIF)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified May 2012 - Condition: Bacterial Pneumonia
Interventions: Drug: IV meropenem; parenteral aminoglycoside; Drug: I.V. Meropenem
Sponsors: University of Florida; University of Florida
Not yet recruiting - verified March 2012 - Condition: Pleuro-pneumonia
Interventions: Drug: Ibuprofen; Drug: Acetaminophen
Sponsors: Rabin Medical Center; Rabin Medical Center
Not yet recruiting - verified January 2012 - Condition: Tetanus Vaccine
Intervention: Biological: Tetanus toxoid vaccine
Sponsors: Epicentre; Epicentre
Not yet recruiting - verified March 2012 - Condition: Pneumonia, Bacterial
Interventions: Drug: Ciprofloxacin (Cipro, BAYQ3939); Drug: Ciprofloxacin (Cipro, BAYQ3939)
Sponsors: Bayer; Bayer
Not yet recruiting - verified April 2012 - Condition: Acute Upper Respiratory Tract Infection and Acute Bacterial Rhinosinusitis
Intervention:
Sponsors: Oulu University Hospital; Oulu University Hospital; Finnish Defense Forces; The Central Hospital of Kajaani; Huslab, Clinical Microbiology, Virology and Immunology; University of Oulu
Recruiting - verified April 2012 - Conditions: Neisseria Meningitidis; Bacterial Infections; Virus Diseases
Interventions: Biological: V419 (PR5I); Biological: Prevenar 13; Biological: NeisVac-C; Biological: MENJUGATE; Biological: MENITORIX; Biological: M-M-RVAXPRO
Sponsors: Sanofi Pasteur MSD; Sanofi Pasteur MSD
Recruiting - verified May 2012 - Condition: Pseudomonas Aeruginosa Infection
Interventions: Biological: IC43 Pseudomonas Aeruginosa; Drug: phosphate buffered saline (PBS)
Sponsors: Intercell AG; Intercell AG
Recruiting - verified March 2012 - Condition: Bacterial Vaginosis
Interventions: Drug: Lactobacillus acidophilus; Drug: Placebo
Sponsors: Università degli Studi di Brescia; Università degli Studi di Brescia; Azienda Ospedaliera Spedali Civili di Brescia
Recruiting - verified March 2012 - Condition: Hidradenitis Suppurativa
Interventions: Drug: Water for injection; Drug: Anakinra
Sponsors: University of Athens; University of Athens
Recruiting - verified March 2012 - Condition: Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Interventions: Drug: CAZ-AVI; Drug: Doripenem; Drug: Either 500 mg of Ciprofloxacin (oral); Drug: or 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
Sponsors: AstraZeneca; AstraZeneca; Cerexa, Inc.
Not yet recruiting - verified May 2012 - Condition: Clostridium Difficile Infection
Interventions: Drug: Fidaxomicin; Drug: Placebo
Sponsors: Washington University School of Medicine; Washington University School of Medicine; Centers for Disease Control and Prevention
Not yet recruiting - verified March 2012 - Condition: Rheumatic Heart Disease
Intervention:
Sponsors: University Hospital Inselspital, Berne; University Hospital Inselspital, Berne; B.P. Koirala Institute of Health Sciences
Not yet recruiting - verified March 2012 - Condition: Latent Tuberculosis Infection
Intervention: Other: Cell phone text messages
Sponsors: University of British Columbia; University of British Columbia; British Columbia Cancer Agency
Not yet recruiting - verified March 2012 - Conditions: Tuberculosis; Filariasis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2012 - Conditions: Diabetic Foot; Foot Ulcer; Leg Ulcer; Bacteremia; Infection
Interventions: Biological: Antibody assays for S. aureus; Biological: Basic blood work
Sponsors: Centre Hospitalier Universitaire de Nīmes; Centre Hospitalier Universitaire de Nīmes
Not yet recruiting - verified March 2012 - Condition: Clostridium Difficile Infection
Intervention:
Sponsors: Yonsei University; Yonsei University
Recruiting - verified March 2012 - Conditions: Diphtheria; Tetanus; Poliomyelitis
Intervention: Biological: Diphtheria, tetanus, polio and pertussis vaccination
Sponsors: Sanofi Pasteur MSD; Sanofi Pasteur MSD
Recruiting - verified May 2012 - Condition: Infection of Skin and/or Subcutaneous Tissue
Intervention: Behavioral: Implemented procedure
Sponsors: Federico II University; Federico II University
Recruiting - verified March 2012 - Condition: Bacterial Meningitis
Interventions: Drug: Infusion with paracetamol; Drug: Bolus without paracetamol
Sponsors: Helsinki University; Helsinki University; Foundation for Paediatric Research, Finland
Recruiting - verified February 2012 - Condition: Bacterial Meningitis
Intervention: Biological: Meningococcal ACWY conjugate vaccine
Sponsors: Novartis; Novartis; Novartis Vaccines
Recruiting - verified April 2012 - Condition: Meningococcal Infection
Intervention: Procedure: blood sampling
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified April 2012 - Condition: Latent Tuberculosis Infection
Interventions: Behavioral: Self Administered Therapy (SAT); Behavioral: SMS reminders; Drug: isoniazid and rifapentine
Sponsors: Centers for Disease Control and Prevention; Centers for Disease Control and Prevention
Not yet recruiting - verified April 2012 - Condition: Adenoviral Conjunctivitis
Interventions: Drug: NVC-422 Ophthalmic Solution, 0.33%; Drug: Vehicle Ophthalmic Solution
Sponsors: NovaBay Pharmaceuticals, Inc.; NovaBay Pharmaceuticals, Inc.
Recruiting - verified May 2012 - Conditions: Pertussis; Whooping Cough; Tetanus; Lockjaw; Diphtheria
Intervention: Biological: Acellular Pertussis and Acellular Pertussis in combination with Tetanus and Diphtheria booster vaccine
Sponsors: Novartis; Novartis Vaccines
Recruiting - verified May 2012 - Conditions: Infections; Community Acquired Pneumonia
Interventions: Drug: Ceftaroline fosamil; Drug: Ceftriaxone; Drug: amoxicillin clavulanate
Sponsors: Cerexa, Inc.; Cerexa, Inc.; AstraZeneca
Not yet recruiting - verified February 2012 - Condition: Bacterial Infections
Intervention: Dietary Supplement: xylitol
Sponsors: Kuwait University; Kuwait University; University of Turku; University of Michigan
Not yet recruiting - verified February 2012 - Conditions: Vibrio Cholerae; Cholera
Interventions: Biological: Killed Bivalent (O1 and O139) whole cell oral cholera vaccine; Biological: Placebo
Sponsors: International Vaccine Institute; International Vaccine Institute; Armauer Hansen Research Institute, Ethiopia; Federal Ministry of Health, Ethiopia; Shantha Biotechnics Limited, India
Not yet recruiting - verified January 2012 - Conditions: Pneumonia, Bacterial; Community-acquired
Interventions: Drug: Ceftaroline; Drug: Levofloxacin
Sponsors: Michigan State University; Gary E. Stein, Pharm.D.; Forest Laboratories
Recruiting - verified February 2012 - Conditions: Meningitis; Gram-Positive Bacteria
Intervention: Drug: Daptomycin
Sponsors: University Hospital Inselspital, Berne; University Hospital Inselspital, Berne
Recruiting - verified April 2012 - Conditions: Skin and Subcutaneous Tissue Bacterial Infections; Wound Infection; Cutaneous Abscess; Burn Infection; Cellulitis
Intervention: Drug: AFN-12520000
Sponsors: Affinium Pharmaceuticals, Ltd; Affinium Pharmaceuticals, Ltd
Recruiting - verified May 2012 - Conditions: Major Cutaneous Abscess; Cellulitis; Erysipelas
Intervention: Drug: TR701 FA
Sponsors: Trius Therapeutics, Inc.; Trius Therapeutics, Inc.; Bayer
Recruiting - verified January 2012 - Condition: Tuberculosis
Interventions: Other: Xpert; Other: Smear
Sponsors: University of Cape Town; University of Cape Town
Recruiting - verified February 2012 - Conditions: HIV; Syphilis
Intervention: Device: MBIO POC combined HIV syphilis test ( SnapEsi)
Sponsors: Program for Appropriate Technology in Health; Program for Appropriate Technology in Health; Walter Reed Army Institute of Research (WRAIR); Kenya Medical Research Institute
Recruiting - verified January 2012 - Condition: Mycobacterium Tuberculosis
Interventions: Drug: AZD5847; Drug: Rifafour
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified October 2011 - Daptomycin Versus Vancomycin in the Treatment of Nosocomial or Healthcare-associated MRSA BacteremiaConditions: Nosocomial Infection; Healthcare-associated Infection
Interventions: Drug: vancomycin monotherapy; Drug: daptomycin monotherapy
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris; Novartis
Not yet recruiting - verified December 2011 - Condition: Clostridium Difficile Infection
Interventions: Biological: MK-6072; Biological: MK-3415A; Biological: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Helicobacter Pylori Infection
Intervention:
Sponsors: Southwest Oncology Group; Southwest Oncology Group; University of Michigan; Graham Environmental Sustainability Inst.; Hope Foundation
Recruiting - verified January 2012 - Conditions: Gastrointestinal Ulcer Haemorrhage; Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
Interventions: Drug: Lansoprazole 30mg, Clarithromycin 500mg, Metronidazole 400mg; Drug: Placebo lansoprazole 30mg, clarithromycin 500mg, metronidazole 400mg
Sponsors: University of Nottingham; University of Nottingham; Nottingham University Hospitals NHS Trust; University of Southampton; University of Durham; University of Birmingham; University of Oxford
Not yet recruiting - verified January 2012 - Condition: Inflammatory Rheumatism
Intervention: Behavioral: Telenursing
Sponsors: University of Applied Sciences of Western Switzerland; University of Applied Sciences of Western Switzerland; Swiss National Science Foundation; Réseau d'Etudes aux Confins de la Santé et du Social (RECSS)(HES-SO); University of Lausanne Hospitals; Consultation Multisite Romande de Rhumatologie Pédiatrique; Ligue Genevoise contre le Rhumatisme
Recruiting - verified January 2012 - A Prospective Observational Study of Patients With Drug Resistant Acinetobacter Baumannii BacteremiaCondition: Acinetobacter Bacteraemia
Intervention:
Sponsors: National Taiwan University Hospital; National Taiwan University Hospital; Far Eastern Memorial Hospital
Recruiting - verified January 2012 - Conditions: Cystic Fibrosis; Methicillin-resistant Staphylococcus Aureus
Intervention: Drug: Vancomycin
Sponsors: Case Western Reserve University; Case Western Reserve University; Cystic Fibrosis Foundation
Recruiting - verified January 2012 - Condition: Infective Endocarditis
Interventions: Other: Integrated rehabilitation; Other: Usual follow-up
Sponsors: Rigshospitalet, Denmark; Rigshospitalet, Denmark; University Hospital, Gentofte, Copenhagen; Copenhagen Trial Unit, Center for Clinical Intervention Research
Recruiting - verified January 2012 - Condition: Shigellosis
Interventions: Biological: Shigella flexneri 2a whole cell killed vaccine (Sf2aWC); Biological: Shigella flexneri 2a whole cell killed vaccine (Sf2aWC); Biological: Shigella flexneri 2a whole cell killed vaccine (Sf2aWC); Biological: Shigella flexneri 2a whole cell killed vaccine (Sf2aWC)
Sponsors: Program for Appropriate Technology in Health; Program for Appropriate Technology in Health
Recruiting - verified January 2012 - Conditions: Listeriosis; Pregnancy Complications; Infectious; Central Nervous System Infections; Septicemia; Sepsis; Listeria Monocytogenes
Intervention:
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris; Institut Pasteur; French National sanitory
Recruiting - verified February 2012 - Condition: H. Pylori Infection
Interventions: Drug: TAK-438; Drug: Lansoprazole; Drug: Amoxicillin; Drug: Clarithromycin
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Pharmaceutical Company Limited
Recruiting - verified May 2012 - Conditions: Intestinal Tuberculosis; Pulmonary Tuberculosis; Crohn's Disease
Intervention:
Sponsors: Lovisenberg Diakonale Hospital; Lovisenberg Diakonale Hospital; Helse Sor-Ost; The Unger-Vetlesen Medical Fund, Jersey, C.I; Odd Fellow Medical Fund, Norway
Recruiting - verified December 2011 - Condition: Pneumococcal Infections
Interventions: Biological: Pneumococcal Conjugate Vaccine (V114); Biological: Pneumococcal Polysaccharide Vaccine; Biological: Pneumococcal 13-Valent Conjugate Vaccine
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Prophylaxis of Lyme Borreliosis
Interventions: Biological: Multivalent recombinant OspA Lyme Borreliosis Vaccine; Biological: Multivalent recombinant OspA Lyme Borreliosis Vaccine; Biological: Multivalent recombinant OspA Lyme Borreliosis Vaccine
Sponsors: Baxter Healthcare Corporation; Baxter Healthcare Corporation
Recruiting - verified January 2012 - Condition: Pulmonary Tuberculosis
Interventions: Drug: M (400 mg) Pa (100 mg) Z (1500 mg); Drug: M (400 mg) Pa (200 mg) Z (1500 mg); Drug: Rifafour; Drug: M (400 mg) Pa (200 mg) Z (1500 mg)
Sponsors: Global Alliance for TB Drug Development; Global Alliance for TB Drug Development
Not yet recruiting - verified December 2011 - Conditions: Skin and Soft Tissue Abscess; Methicillin-resistant Staphylococcus Aureus (MRSA) Infection
Intervention: Drug: Oral Clindamycin
Sponsors: Children's Memorial Hospital; Children's Memorial Hospital
Recruiting - verified December 2011 - Condition: Tuberculosis
Interventions: Biological: Aerosol inhaled MVA85A; Biological: Intradermal MVA85A
Sponsors: University of Oxford; University of Oxford
Recruiting - verified January 2012 - Conditions: Group A Streptococcus; Strep Throat
Intervention:
Sponsors: Quidel Corporation; Quidel Corporation
Recruiting - verified December 2011 - Conditions: HIV Infections; Tuberculosis
Interventions: Drug: Isoniazid (INH); Drug: Placebo for isoniazid (INH)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified May 2012 - Condition: Cholera
Intervention:
Sponsors: International Vaccine Institute; International Vaccine Institute; Department of Health and Family Welfare, Orissa; Regional Medical Research Center, Orissa
Not yet recruiting - verified March 2012 - Condition: Strep Throat
Intervention:
Sponsors: IND Diagnostic Inc.; IND Diagnostic Inc.
Recruiting - verified March 2012 - Condition: Complicated Skin and Soft Tissue Infection
Interventions: Drug: Ceftaroline fosamil; Drug: Vancomycin; Drug: Aztreonam
Sponsors: AstraZeneca; AstraZeneca; Cerexa, Inc.
Not yet recruiting - verified March 2012 - Condition: Tuberculosis
Intervention:
Sponsors: Epicentre; Epicentre; Mbarara University of Science and Technology; Medecins Sans Frontieres
Not yet recruiting - verified December 2011 - Conditions: Pulmonary Infections; Pseudomonas Aeruginosa in Cystic Fibrosis
Intervention: Drug: Tobramycin inhalation powder
Sponsors: Novartis; Novartis
Recruiting - verified January 2012 - Conditions: Pneumonia; Bronchopneumonia; Pleuropneumonia; Pneumonia, Bacterial; Pneumonia, Viral
Intervention: Other: Discontinuation of antibiotic therapy
Sponsors: University of Milan; University of Milan; University of Milano Bicocca
Recruiting - verified March 2012 - Condition: Hidradenitis Suppurativa
Intervention: Drug: anakinra
Sponsors: University of California, San Francisco; University of California, San Francisco
Not yet recruiting - verified March 2012 - Condition: Urinary Tract Infection
Interventions: Drug: Ibuprofen; Drug: Fosfomycin-Trometamol
Sponsors: Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH; Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH; University Medical Center Goettingen
Recruiting - verified December 2011 - Conditions: Bacterial Infections; Virus Diseases
Interventions: Biological: V419; Biological: Rotavirus vaccine; Biological: Prevenar 13; Biological: INFANRIX hexa
Sponsors: Sanofi Pasteur MSD; Sanofi Pasteur MSD; Merck
Recruiting - verified May 2012 - Conditions: Lower Limb Ischaemia; Aneurysm
Intervention: Other: bacterial samples
Sponsors: North Carelia Central Hospital; North Carelia Central Hospital
Recruiting - verified January 2012 - Conditions: Meningococcal Meningitis; Meningococcal Infections
Interventions: Biological: meningococcal meningitis conjugate vaccine, quadrivalent; Biological: meningococcal meningitis conjugate vaccine, quadrivalent
Sponsors: JN-International Medical Corporation; JN-International Medical Corporation
Recruiting - verified March 2012 - Conditions: Meningococcal Disease,; Meningococcal Meningitis,; Prevention Vaccination
Intervention: Biological: Recombinant Meningococcal B + Outer Membrane Vesicle New Zealand Vaccine
Sponsors: Novartis; Novartis Vaccines
Not yet recruiting - verified May 2012 - Conditions: Seizures; Pneumococcal Meningitis
Interventions: Drug: Phenytoin; Drug: placebo
Sponsors: Hospital Universitari de Bellvitge; M. Carmen Cabellos Minguez; Hospital Universitari de Bellvitge; Hospital Vall d; Germans Trias i Pujol Hospital; Hospital Clinic of Barcelona; Fundació Institut de Recerca de l; Hospitales Universitarios Virgen del Rocío; Hospital Universitario La Paz; Hospital Universitario Ramon y Cajal; Hospital Juan Canalejo; Hospital Mutua de Terrassa; Hospital Virgen Macarena
Not yet recruiting - verified November 2011 - Condition: Helicobacter Pylori Infection
Intervention: Other: OCA 10
Sponsors: Hospital Donostia; Hospital Donostia
Recruiting - verified December 2011 - Condition: Tuberculosis
Interventions: Biological: VPM1002; Biological: BCG
Sponsors: Vakzine Projekt Management GmbH; Vakzine Projekt Management GmbH; Children's Infectious Diseases Clinical Research Unit (KID-CRU), South Africa; Triclinium Johannesburg, South Africa; Stellenbosch University, Cape Town, South Africa; HJ-CTC George, South Africa
Recruiting - verified February 2012 - Condition: Lyme Borreliosis
Intervention: Drug: Doxycycline
Sponsors: University Medical Centre Ljubljana; University Medical Centre Ljubljana
Recruiting - verified November 2011 - Condition: Acute Adenoviral Conjunctivitis
Interventions: Drug: FST-100; Drug: FST-100 (Component #1); Drug: FST-100 Vehicle
Sponsors: Foresight Biotherapeutics; Foresight Biotherapeutics
Not yet recruiting - verified March 2012 - Condition: Bacterial Vaginosis
Intervention: Drug: Trimo-San gel
Sponsors: Medstar Research Institute; Medstar Research Institute; University of New Mexico
Recruiting - verified November 2011 - Condition: Complicated Intra-Abdominal Infection
Interventions: Drug: CAZ-AVI; Drug: Metronidazole; Drug: Meropenem
Sponsors: AstraZeneca; AstraZeneca; Cerexa, Inc.
Recruiting - verified April 2012 - Condition: Hidradenitis Suppurativa (HS)
Interventions: Biological: adalimumab; Biological: placebo; Biological: adalimumab
Sponsors: Abbott; Abbott
Recruiting - verified March 2012 - Condition: Hidradenitis Suppurativa (HS)
Interventions: Biological: adalimumab; Biological: placebo; Biological: adalimumab
Sponsors: Abbott; Abbott
Recruiting - verified December 2011 - Conditions: Mediastinal Lymphadenopathy; Hilar Lymphadenopathy; Carcinoma; Lymphoma; Sarcoidosis; Mycobacterial Disease
Intervention: Device: Endobronchial ultrasound guided lymph node sampling
Sponsors: Royal Brompton & Harefield NHS Foundation Trust; Royal Brompton & Harefield NHS Foundation Trust; Chelsea and Westminster NHS Foundation Trust; University of Heidelberg
Recruiting - verified November 2011 - Condition: Complicated Intra-Abdominal Infection
Interventions: Drug: CAZ-AVI; Drug: Metronidazole; Drug: Meropenem
Sponsors: AstraZeneca; AstraZeneca; Cerexa, Inc.
Recruiting - verified April 2012 - Conditions: HIV; Syphilis; Gonorrhea; Chlamydia
Interventions: Behavioral: Mujer Segura; Behavioral: CENSIDA counseling program
Sponsors: University of California, San Diego; University of California, San Diego; National Institute of Mental Health (NIMH)
Recruiting - verified November 2011 - Condition: Shigella
Interventions: Biological: CVD 1208S, a Shigella flexneri 2a live, oral vaccine; Other: Placebo
Sponsors: University of Maryland; University of Maryland; Program for Appropriate Technology in Health
Recruiting - verified February 2012 - Condition: Methicillin-Resistant Staphylococcus Aureus
Interventions: Drug: Retapamulin; Drug: Placebo
Sponsors: University of California, Irvine; University of California, Irvine; Agency for Healthcare Research and Quality (AHRQ)
Not yet recruiting - verified October 2011 - Condition: Helicobacter Pylori Infection
Interventions: Drug: PPI, amoxicillin, metronidazole and clarithromycin; Drug: PPI, amoxicillin, metronidazole and clarithromycin
Sponsors: Infante, Javier Molina, M.D.; Infante, Javier Molina, M.D.
Recruiting - verified October 2011 - Conditions: Hepatitis; Tuberculosis
Intervention:
Sponsors: All India Institute of Medical Sciences, New Delhi; All India Institute of Medical Sciences, New Delhi
Recruiting - verified February 2012 - Condition: Anthrax
Interventions: Drug: ETI-204, "Anthim"; Drug: placebo
Sponsors: Elusys Therapeutics; Elusys Therapeutics
Recruiting - verified October 2011 - Conditions: Sepsis; Bacteremia; Fungemia
Intervention: Other: Antibiotic regimen
Sponsors: Instituto do Coracao; Instituto do Coracao; Fundação de Amparo à Pesquisa do Estado de São Paulo
Not yet recruiting - verified October 2011 - Condition: Helicobacter Pylori Infection
Interventions: Dietary Supplement: Progastria; Dietary Supplement: Placebo
Sponsors: St Marina University Hospital, Varna, Bulgaria; St Marina University Hospital, Varna, Bulgaria
Recruiting - verified February 2012 - Condition: Tuberculosis
Interventions: Other: GeneXpert; Other: LED Microscopy
Sponsors: Johns Hopkins University; Johns Hopkins University
Not yet recruiting - verified April 2012 - Conditions: Poliomyelitis; Haemophilus Influenzae Type b Disease; Hepatitis B; Diphtheria; Pertussis; Tetanus
Interventions: Biological: Combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus and Haemophilus influenzae type b vaccine (GSK217744) - Formulation A; Biological: Combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus and Haemophilus influenzae type b vaccine (GSK217744) - Formulation B; Biological: Infanrix hexaTM; Biological: Pfizer's 13-valent pneumococcal polysaccharide conjugate vaccine (Prevenar 13®)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012 - Conditions: Streptococcal Infection; Gram-positive Bacterial Infection; Bacterial Infection
Interventions: Biological: Group B streptococcus vaccine; Biological: Placebo
Sponsors: Novartis; Novartis; Novartis Vaccines
Recruiting - verified May 2012 - Conditions: Dyspepsia; H. Pylori Infection
Interventions: Dietary Supplement: L. reuteri; Dietary Supplement: Placebo
Sponsors: Lama Medical Care s.r.o.; Lama Medical Care s.r.o.; BioGaia AB
Not yet recruiting - verified October 2011 - Conditions: Chronic Q-fever; Aortic Aneurysm, Abdominal; Q Fever; Aneurysm; Vascular Graft Infection
Intervention:
Sponsors: Jeroen Bosch Ziekenhuis; Jeroen Bosch Ziekenhuis; ZonMw: The Netherlands Organisation for Health Research and Development
Recruiting - verified October 2011 - Condition: Bacterial Vaginosis
Interventions: Dietary Supplement: Vitamin D3 (cholecalciferol); Dietary Supplement: Placebo
Sponsors: Ohio State University; Ohio State University
Recruiting - verified October 2011 - Conditions: Staphylococcal Infections; Yeast Infections; Candidiasis
Interventions: Biological: NDV-3 vaccine with alum administered IM; Biological: NDV-3 vaccine without alum administered IM; Biological: Placebo administered ID; Biological: NDV-3 vaccine without alum administered ID
Sponsors: NovaDigm Therapeutics, Inc.; NovaDigm Therapeutics, Inc.; Department of Defense
Recruiting - verified October 2011 - Conditions: Pneumonia; Pneumococcal Infections; Streptococcus Pneumoniae Infections
Interventions: Biological: Pneumococcal Vaccine High Dose (Formulation 1); Biological: Tris buffered saline (Placebo); Biological: Pneumococcal Vaccine High Dose (Formulation 1); Biological: Tris buffered saline (Placebo); Biological: Pneumococcal Vaccine Low Dose (Formulation 2); Biological: Tris buffered saline (Placebo); Biological: Pneumococcal Vaccine Middle Dose (Formulation 3); Biological: Pneumococcal Vaccine Middle Dose (Formulation 4); Biological: Tris buffered saline (Placebo); Biological: Pneumococcal Vaccine High Dose (Formulation 1); Biological: Tris buffered saline (Placebo)
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified March 2012 - Conditions: Streptococcus Infection; Pregnancy
Intervention:
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston
Recruiting - verified September 2011 - Conditions: Infection; Bone Neoplasms
Intervention: Procedure: Prophylactic Cefazolin Antibiotic Regimen
Sponsors: McMaster University; Michelle Ghert
Not yet recruiting - verified April 2012 - Conditions: Peptic Ulcer; Helicobacter Pylori Infection
Intervention: Procedure: 23S rRNA point mutation test of Helicobacter pylori
Sponsors: The Catholic University of Korea; Jin Il Kim; Korean College of Helicobacter and Upper Gastrointestinal Research
Recruiting - verified May 2012 - Condition: Meningococcal Disease
Intervention: Biological: MenACWY-CRM
Sponsors: Novartis; Novartis Vaccines; Novartis
Recruiting - verified May 2012 - Condition: Meningococcal Disease
Intervention: Biological: MenACWY-CRM
Sponsors: Novartis; Novartis Vaccines
Recruiting - verified May 2012 - Conditions: Pneumococcal Infections; HIV Infections
Interventions: Biological: PPV-23 Vaccine; Biological: PCV-13 Vaccine; Biological: Placebo Vaccine
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified April 2012 - Condition: Botulism
Intervention: Drug: 3,4-diaminopyridine
Sponsors: Centre Hospitalier Universitaire, Amiens; Centre Hospitalier Universitaire, Amiens
Recruiting - verified October 2011 - Condition: Strep Throat
Intervention:
Sponsors: Quidel Corporation; Quidel Corporation
Recruiting - verified September 2011 - Condition: Methicillin-resistant Staphylococcus Aureus
Interventions: Drug: Rifampin; Drug: Doxycycline; Other: 2% mupirocin ointment; Other: 4% chlorhexidine gluconate
Sponsors: Horizon Health Network, Saint John Zone; Horizon Health Network, Saint John Zone
Recruiting - verified September 2011 - Condition: Skin Infections, Bacterial
Intervention: Drug: ALTARGO(retapamulin)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified May 2012 - Conditions: Gonorrhea; Chlamydia; Trichomoniasis; Syphilis; HIV Infections
Intervention: Behavioral: Intervention
Sponsors: University of Kentucky; University of Kentucky; National Institute of Mental Health (NIMH)
Not yet recruiting - verified September 2011 - Conditions: Diphtheria; Tetanus; Pertussis; Poliomyelitis
Intervention: Biological: TETRAXIM™: Combined adsorbed diphtheria, tetanus, acellular pertussis and enhanced inactivated polio
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified March 2012 - Condition: Recurrent Bacterial Vaginosis (BV)
Interventions: Drug: 1% SPL7013 Gel; Drug: 3% SPL7013 Gel; Drug: placebo gel
Sponsors: Starpharma Pty Ltd; Starpharma Pty Ltd
Recruiting - verified April 2012 - Condition: Tuberculosis
Interventions: Drug: Silymarin; Drug: Placebo
Sponsors: Seoul National University Hospital; Seoul National University Hospital
Recruiting - verified September 2011 - Condition: Bacterial Infection
Intervention: Other: Retrospective examination by experts whether care given fo child admitted at the ICU for suspicion of bacterial infection (not nosocomial) was optimal or not
Sponsors: Nantes University Hospital; Nantes University Hospital
Recruiting - verified September 2011 - Conditions: Meningococcal Disease; Meningococcal Meningitis
Interventions: Biological: Meningococcal C conjugate vaccine; Biological: Meningococcal C conjugate vaccine; Biological: Meningococcal C conjugate vaccine
Sponsors: Novartis; Novartis; Novartis Vaccines
Recruiting - verified March 2012 - Conditions: Cat-scratch Disease; Bartonella Infections
Interventions: Drug: prednison and azithromycin; Drug: prednison, azithromycin; Drug: prednison, Azenil
Sponsors: Tel-Aviv Sourasky Medical Center; Tel-Aviv Sourasky Medical Center
Not yet recruiting - verified November 2011 - Conditions: Multidrug-resistant Tuberculosis; Extensively Drug-resistant Tuberculosis
Intervention: Drug: Addition of different doses of clarithromycin.
Sponsors: University Medical Centre Groningen; University Medical Centre Groningen
Recruiting - verified January 2012 - Conditions: HIV Infection; Tuberculosis
Intervention:
Sponsors: Lund University; Lund University; Swedish International Development Cooperation Agency (SIDA); Swedish Civil Contingencies Agency (MSB)
Recruiting - verified April 2012 - Conditions: Mycobacterium Ulcerans Disease; Buruli Ulcer
Intervention: Procedure: surgical intervention on Buruli ulcer
Sponsors: University Medical Centre Groningen; University Medical Centre Groningen; PNLUB, Ministère de la santé, Cotonou, République du Bénin.; Laboratoire de Référence des Mycobactéries (LRM) Cotonou
Recruiting - verified September 2011 - Conditions: Cystic Fibrosis; Pneumonia; Pseudomonas Aeruginosa Infection
Intervention: Drug: meropenem
Sponsors: Hartford Hospital; Joseph Kuti; Thrasher Research Fund
Recruiting - verified April 2012 - Conditions: Immune Reconstitution Inflammatory Syndrome; Immune Reconstitution Syndrome; Tuberculosis; HIV-infection/Aids
Interventions: Drug: Dexamethasone; Drug: Atorvastatin; Drug: Naproxen; Drug: Placebo
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; Pfizer; Minnesota Medical Foundation
Not yet recruiting - verified April 2012 - Conditions: Cirrhosis; Ascites; Nosocomial Spontaneous Bacterial Peritonitis
Interventions: Drug: Daptomycin + Meropenem; Drug: Ceftazidime
Sponsors: University of Padova; University of Padova
Recruiting - verified October 2011 - Conditions: Cheyne-Stokes Respiration; Heart Valve Disease; Central Sleep Apnea
Intervention: Procedure: heart valve replacement
Sponsors: Nanjing Medical University; Nanjing Medical University
Recruiting - verified February 2012 - Condition: Skin and Subcutaneous Tissue Bacterial Infections
Interventions: Drug: TR-701 FA for 6 days followed by 4 days of placebo; Drug: Linezolid for 10 days of treatment
Sponsors: Trius Therapeutics, Inc.; Trius Therapeutics, Inc.
Recruiting - verified October 2011 - Condition: Multidrug Resistant Tuberculosis
Interventions: Drug: Delamanid; Drug: Placebo
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified May 2012 - Condition: Tuberculosis
Interventions: Biological: GSK Biologicals' investigational TB vaccine GSK 692342; Biological: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified November 2011 - Conditions: HIV; Tuberculosis
Interventions: Drug: Raltegravir; Drug: Rifampicin; Drug: Raltegravir
Sponsors: University of Liverpool; Helen Reynolds; Royal Liverpool and Broadgreen University Hospitals NHS Trust
Not yet recruiting - verified September 2011 - Condition: Meningococcal Meningitis
Interventions: Biological: placebo+ Combined Tetanus, Reduced Diphtheria Toxoid Acellular Pertussis Vaccine+Quadrivalent Human Papillomavirus Vaccine; Biological: MenACWY Conjugate Vaccine+Combined Tetanus, Reduced Diphtheria Toxoid,Acellular Pertussis Vaccine +Quadrivalent Human Papillomavirus Vaccine
Sponsors: Novartis; Novartis; Novartis Vaccines
Recruiting - verified April 2012 - Conditions: Enteric Fever; Typhoid Fever
Interventions: Drug: Ceftriaxone; Drug: Gatifloxacin
Sponsors: Oxford University Clinical Research Unit, Vietnam; Oxford University Clinical Research Unit, Vietnam; Oxford University Clinical Research Unit, Nepal; Patan Academy of Health Sciences, Nepal; Patan Hospital, Nepal; Civil Hospital, Nepal
Recruiting - verified April 2012 - Conditions: Streptococcal Infections; Gram-Positive Bacterial Infections; Bacterial Infections
Intervention: Biological: Group B streptococcus vaccine
Sponsors: Novartis; Novartis Vaccines
Recruiting - verified May 2012 - Condition: Staphylococcal Skin Infections
Interventions: Drug: Daptomycin; Drug: Vancomycin
Sponsors: Cubist Pharmaceuticals; Cubist Pharmaceuticals
Recruiting - verified March 2012 - Condition: Tuberculosis
Intervention:
Sponsors: Epicentre; Epicentre; Mbarara University of Science and Technology; Medecins Sans Frontieres
Not yet recruiting - verified August 2011 - Conditions: Conjunctival Infections, Irritations and Inflammations; Hypertrophy; Conjunctiva; Corneal Pannus; Corneal Epithelial Wound
Intervention: Other: contact lens wear
Sponsors: Buddhist Tzu Chi General Hospital, Taipei; Buddhist Tzu Chi General Hospital, Taipei; National Taiwan University Hospital
Recruiting - verified December 2011 - Conditions: Bile Duct Stricture; Choledocholithiasis
Intervention: Other: Blood draw for culture
Sponsors: Stanford University; Stanford University; Boston Scientific Corporation
Recruiting - verified August 2011 - Condition: Bacterial Vaginosis
Interventions: Drug: Vaginal capsules of lactobacilli; Drug: Vaginal capsules of lactobacilli
Sponsors: The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine; The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine; Ministry of Health, China
Recruiting - verified August 2011 - Condition: Bacteremia
Intervention: Other: Blood Culture QI Program
Sponsors: Vanderbilt University; Vanderbilt University; Community Health Systems; Society for Academic Emergency Medicine; CareFusion; Trinity Medical Center, Birmingham; Carolinas Hospital System; Dyersburg Regional Hospital; Gateway Medical Center; Crestwood Medical Center; Jackson Regional Hospital
Recruiting - verified August 2011 - Conditions: Abscess; Wound Infection; Surgical Site Infection; Cellulitis
Interventions: Drug: IV Dalbavancin; Drug: Vancomycin/Linezolid
Sponsors: Durata Therapeutics, Inc.; Durata Therapeutics, Inc.
Recruiting - verified March 2012 - Conditions: Intensive Care Patients; Cardiac Surgical Telemetry Patients
Interventions: Device: Disposable ECG leadwires; 5 and 6 lead sets; Other: No intervention
Sponsors: The Cleveland Clinic; The Cleveland Clinic
Recruiting - verified March 2012 - Condition: Tuberculosis
Intervention: Drug: Higher-Dose Rifampin
Sponsors: Harvard University Faculty of Medicine; Harvard University Faculty of Medicine; National Institute of Allergy and Infectious Diseases (NIAID); Sanofi-Aventis; Harvard School of Public Health; Brigham and Women's Hospital; University of Liverpool; Universidade Federal do Espírito Santo; Socios En Salud Sucursal Perú; St George's, University of London; University of Florida
Not yet recruiting - verified August 2011 - Conditions: Hemolytic-uremic Syndrome; Escherichia Coli Infections
Intervention: Other: HUS standard coverage care (including in ICU)
Sponsors: University Hospital, Bordeaux; University Hospital, Bordeaux
Recruiting - verified September 2011 - Conditions: Typhoid Fever; Enteric Fever; Typhoid
Interventions: Biological: Vaccine placebo (excipients only); Biological: Ty21a; Biological: M10ZH09 vaccine
Sponsors: University of Oxford; University of Oxford; Wellcome Trust; Imperial College London; University of Maryland
Recruiting - verified December 2011 - Condition: Bacterial, Viral and Other Infectious Agents
Intervention: Other: Removal of triclosan-containing cleaning products from household.
Sponsors: Stanford University; Stanford University
Recruiting - verified September 2011 - Conditions: Tuberculosis; HIV Infections
Interventions: Drug: Rifapentine (RPT); Drug: Isoniazid (INH); Dietary Supplement: Pyridoxine (Vitamin B6)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified May 2012 - Conditions: HIV Infection; Tuberculosis
Interventions: Drug: Experimental: Empiric TB treatment; Drug: ART only arm
Sponsors: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); European and Developing Countries Clinical Trials Partnership (EDCTP)
Not yet recruiting - verified March 2011 - Condition: Haemophilus Influenzae Type B Infection
Intervention: Biological: Haemophilus influenza type b conjugate vaccine
Sponsors: Novartis; Novartis Vaccines
Recruiting - verified February 2012 - Condition: Prophylaxis Against Diphtheria, Tetanus
Interventions: Biological: GC1107; Biological: SK Td vaccine
Sponsors: Green Cross Corporation; Green Cross Corporation
Not yet recruiting - verified May 2011 - Condition: Group B Streptococcal Infection
Intervention: Dietary Supplement: GR-1, RC-14
Sponsors: China Medical University Hospital; China Medical University Hospital
Recruiting - verified April 2012 - Condition: Clostridium Difficile Infection
Interventions: Procedure: Fecal Transplantation; Drug: Vancomycin
Sponsors: McMaster University; McMaster University; St. Joseph's Healthcare Hamilton
Not yet recruiting - verified July 2011 - Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With ImpetigoCondition: Impetigo
Interventions: Drug: ozenoxacin placebo; Drug: retapamulin 1% ointment; Drug: ozenoxacin 1% cream
Sponsors: Ferrer Internacional S.A.; Ferrer Internacional S.A.
Not yet recruiting - verified March 2012 - Conditions: Crohn's Disease; Intestinal Tuberculosis
Intervention:
Sponsors: Asan Medical Center; Asan Medical Center
Recruiting - verified September 2011 - Condition: Bacteremia
Intervention:
Sponsors: Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Merck
Not yet recruiting - verified January 2011 - Condition: Tuberculosis
Interventions: Procedure: Xpert MTB/RIF assay; Procedure: Smear microscopy
Sponsors: University of Cape Town; University of Cape Town; Biomedical Research and Training Institute; University of Zimbabwe; University of Zambia; Medical Research Council, South Africa; Mbeya medical research program; McGill University; Radboud University; University of Cape Town Lung Institute
Recruiting - verified March 2012 - Condition: Tuberculosis
Interventions: Procedure: Sputum induction; Procedure: standard routine expectorated sputum
Sponsors: University of Cape Town; University of Cape Town
Recruiting - verified March 2012 - Condition: Tuberculosis
Intervention:
Sponsors: Azienda Ospedaliera San Gerardo di Monza; Azienda Ospedaliera San Gerardo di Monza
Recruiting - verified February 2012 - Condition: Vaginosis, Bacterial
Intervention: Drug: Etonogestrel /Ethinyl Estradiol Contraceptive Vaginal Ring
Sponsors: Eastern Virginia Medical School; Eastern Virginia Medical School; Merck
Recruiting - verified April 2012 - Conditions: Hepatitis; Tuberculosis, Pulmonary
Intervention: Drug: isoniazid, rifampin, pyrazinamide
Sponsors: National Taiwan University Hospital; National Taiwan University Hospital
Recruiting - verified July 2011 - Condition: Bacteremia
Intervention:
Sponsors: Charite University, Berlin, Germany; Charite University, Berlin, Germany
Recruiting - verified July 2011 - Conditions: Catheter Related Infection; Bacteremia
Interventions: Other: 30 % ethanol / 4% sodium citrate catheter locking solution; Drug: Heparin 1000 u / ml
Sponsors: University of Manitoba; University of Manitoba
Recruiting - verified July 2011 - Condition: Staphylococcus Aureus
Intervention:
Sponsors: Medical Corps, Israel Defense Force; Medical Corps, Israel Defense Force
Recruiting - verified March 2012 - Condition: Escherichia Coli Infection
Interventions: Biological: Recombinant fimbrial adhesin dscCfaE; Biological: Recombinant fimbrial adhesin dscCfaE; Biological: Recombinant fimbrial adhesin dscCfaE; Biological: Modified E. coli heat labile enterotoxin LTR192G
Sponsors: U.S. Army Medical Research and Materiel Command; U.S. Army Medical Research and Materiel Command
Recruiting - verified August 2011 - Conditions: Tuberculosis, Pulmonary; Mycobacterium Tuberculous; Antitubercular Agents; Tuberculosis, Mulutidrug-Resistant; Extensively Drug-Resistant; Extensibely Drug-Resistant Tuberculosis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012 - Condition: Tuberculosis
Intervention: Drug: nicotine replacement therapy
Sponsors: All India Institute of Medical Sciences, New Delhi; All India Institute of Medical Sciences, New Delhi; University of Cape Town; Sri Venkateswara Institute of Medical Sciences University
Recruiting - verified January 2012 - Condition: Plague
Interventions: Biological: Flagellin/F1/V; Drug: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2012 - Condition: Community Acquired Pneumonia
Interventions: Drug: BT086; Drug: 1% Human Albumin infusion
Sponsors: Biotest; Biotest
Recruiting - verified August 2011 - Condition: HIV Infection
Interventions: Drug: Atripla (r); Drug: Efavirenz; Drug: Truvada; Drug: Rifampin/isoniazid/pyrazinamide/ethambutol FDC; Drug: Rifampin/isoniazid FDC
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2012 - Condition: Tuberculosis
Interventions: Biological: V7; Other: placebo
Sponsors: Lisichansk Regional Tuberculosis Dispensary; Lisichansk Regional Tuberculosis Dispensary; National Medical University, Ukraine; Immunitor USA Inc.
Recruiting - verified August 2011 - Conditions: Staphylococcus Aureus; Staphylococcal Infections; Drug Resistance; Occupational Medicine
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified May 2011 - Condition: Tuberculosis
Intervention:
Sponsors: Yonsei University; Yonsei University
Recruiting - verified June 2011 - Condition: Cystic Fibrosis
Intervention: Drug: Aztreonam Lysine for Inhalation (AZLI)
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2012 - Condition: Pulmonary Tuberculosis (TB)
Intervention: Drug: Rifampicin
Sponsors: Radboud University; Radboud University; European and Developing Countries Clinical Trials Partnership (EDCTP); Department of Clinical Pharmacy, University Medical Centre St Radboud, The Netherlands.; University Centre for Chronic Diseases Dekkerswald, Groesbeek, NL
Recruiting - verified July 2011 - Conditions: Bacterial Infection; Leukemia; Musculoskeletal Complications; Neutropenia
Interventions: Drug: levofloxacin; Procedure: standard follow-up care
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Acinetobacter Bacteraemia
Intervention:
Sponsors: Taipei Veterans General Hospital,Taiwan; Taipei Veterans General Hospital,Taiwan; Merck
Not yet recruiting - verified June 2011 - Condition: Infections, Pediatrics
Interventions: Drug: Ceftaroline fosamil; Drug: Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam; Drug: Cephalexin or Clindamycin
Sponsors: Cerexa, Inc.; Cerexa, Inc.; AstraZeneca
Recruiting - verified May 2012 - Condition: Tuberculous Meningitis
Intervention:
Sponsors: Xijing Hospital; Xijing Hospital
Recruiting - verified March 2011 - Conditions: Staphylococcal Infections; Staphylococcal Vaccines; Bacterial Infections; Staphylococcal Skin Infections
Interventions: Biological: SA4Ag vaccine low dose; Procedure: Blood draw; Procedure: Colonization swab sample; Biological: SA4Ag vaccine mid dose; Procedure: Blood sample; Procedure: Colonization swab sample; Biological: SA4Ag vaccine high dose; Procedure: Blood draw; Procedure: Colonization swab sample; Biological: Placebo; Procedure: Blood draw; Procedure: Colonization swab sample
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Clostridium Difficile Infection
Intervention: Biological: "synthetic stool" or pure cultures of probiotic intestinal bacteria
Sponsors: Queen's University; Queen's University; The Physicians' Services Incorporated Foundation
Recruiting - verified April 2012 - Conditions: Immunogenicity; Shigellosis
Intervention: Biological: Shigella Sonnei O-SPC/rBRU
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified April 2012 - Conditions: Erythema Migrans; Erythema Chronicum Migrans; Borreliosis; Lyme Disease; Early Lyme Disease
Interventions: Drug: Doxycycline; Drug: Phenoxymethylpenicillin; Drug: Amoxicillin
Sponsors: University of Oslo; University of Oslo; Norwegian Institute of Public Health; Sorlandet Hospital HF; Norwegian University of Life Sciences
Recruiting - verified April 2011 - Conditions: Infection; Skin Diseases, Bacterial; Granuloma
Interventions: Behavioral: Hygiene; Procedure: Usual alcohol care
Sponsors: Ospedale L. Sacco – Polo Universitario; Ospedale L. Sacco – Polo Universitario
Recruiting - verified April 2011 - Conditions: Lung Disease, Obstructive; Tuberculosis
Intervention:
Sponsors: Seoul National University Bundang Hospital; Seoul National University Bundang Hospital
Recruiting - verified June 2011 - Safety and Efficacy Study of Ethanol Locking to Prevent Central Line Infection in Premature NeonatesConditions: Infection Associated With Catheter; Bacteremia; Sepsis
Interventions: Drug: Ethanol lock; Drug: Heparinized saline
Sponsors: East Carolina University; East Carolina University
Recruiting - verified November 2010 - Condition: Tuberculosis
Interventions: Other: GeneXpert MTB/Rif; Other: Observation
Sponsors: Ataulpho de Paiva Foundation; Ataulpho de Paiva Foundation; Bill and Melinda Gates Foundation
Not yet recruiting - verified January 2012 - Conditions: Tuberculosis; Tuberculosis, Pulmonary; Early Gastric Cancer
Intervention:
Sponsors: National Cancer Center, Korea; National Cancer Center, Korea
Recruiting - verified February 2011 - Conditions: Sepsis; Bacteremia; Fungemia
Intervention:
Sponsors: Medical University of Graz; Medical University of Graz
Recruiting - verified May 2011 - Conditions: Diphtheria; Pertussis; Tetanus
Intervention: Biological: Boostrix TM
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified January 2012 - Conditions: Bacterial Infection; Leukemia; Lymphoma
Interventions: Biological: pneumococcal polyvalent vaccine; Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); Arthur G. James Cancer Hospital & Richard J. Solove Research Institute; National Cancer Institute (NCI)
Recruiting - verified September 2011 - Condition: Pseudomonas Aeruginosa Infection
Interventions: Drug: Piperacillin-Tazobactam continuous infusion; Drug: Piperacillin-Tazobactam intermittent infusion
Sponsors: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla; Fundación Pública Andaluza para la gestión de la Investigación en Sevilla; Ministerio de Sanidad y Politica Social; Hospital Universitario Virgen del Rocío; Hospital Universitario Virgen Macarena; Hospital Universitario Son Espases; Hospital Universitario Son Llátzer; Hospital Juan Ramón Jiménez; Hospital Universitario Virgen de las Nieves; Hospital General de Cataluña; Hospital Infanta Sofía; Hospital Universitario Ntra. Sra. de La Candelaria
Recruiting - verified April 2012 - Conditions: Diphtheria; Hepatitis B; Haemophilus Influenzae Type b Disease; Poliomyelitis; Pertussis; Tetanus
Intervention: Biological: Infanrix hexa™
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified April 2012 - Condition: Meningitis, Meningococcal
Interventions: Biological: rLP2086 vaccine; Biological: control
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified April 2012 - Condition: Methicillin-Resistant Staphylococcus Aureus
Intervention:
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Not yet recruiting - verified February 2012 - Condition: Wounds
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Recruiting - verified March 2011 - Conditions: Cystic Fibrosis; Methicillin-resistant Staphylococcus Aureus
Interventions: Drug: Rifampin; Drug: Trimethoprim/Sulfamethoxazole; Drug: Minocycline; Drug: Mupirocin; Drug: chlorhexidine gluconate oral rinse; Drug: 2% Chlorhexidine solution wipes; Behavioral: Environmental Decontamination
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; CF Therapeutics Development Network Coordinating Center; Seattle Children's Hospital; University of Washington; University of Colorado, Denver; Texas Children's Hospital; University of Alabama at Birmingham; St. Louis Children's Hospital; Cook Children's Medical Center; University of Michigan Health System
Recruiting - verified January 2012 - Conditions: Tetanus; Diphtheria; Pertussis; Measles; Polio
Interventions: Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus; Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus; Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus; Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Bacterial Infections
Interventions: Drug: Doripenem; Drug: Doripenem
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2012 - Conditions: Community-Acquired Bacterial Pneumonia; Lung Infection of Individual Not Recently Hospitalized
Interventions: Drug: Ceftaroline; Drug: Ceftriaxone
Sponsors: AstraZeneca; AstraZeneca; Forest Laboratories
Recruiting - verified March 2012 - Condition: Shigellosis
Interventions: Biological: WRSs2; Other: Placebo; Biological: WRSs3
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified April 2012 - Conditions: Meningococcal Disease; Meningococcal Meningitis
Interventions: Biological: Meningococcal B Recombinant Vaccine; Biological: Meningococcal C conjugated Vaccine
Sponsors: Novartis; Novartis Vaccines
Recruiting - verified May 2012 - Condition: Tuberculosis
Interventions: Drug: TMC207; Drug: Rifabutin; Drug: Rifampin
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012 - Conditions: Community-associated Infections; Health-care Acquired Infections; Nosocomial Infections
Intervention: Other: antibiotic treatment of by TREAT/PCR
Sponsors: Rabin Medical Center; Rabin Medical Center
Not yet recruiting - verified October 2011 - Condition: Streptococcus Suis Infection
Intervention:
Sponsors: Oxford University Clinical Research Unit, Vietnam; Oxford University Clinical Research Unit, Vietnam; National Hospital for Tropical Diseases, Vietnam
Recruiting - verified April 2012 - Condition: Tuberculosis Infection
Intervention:
Sponsors: Oxford University Clinical Research Unit, Vietnam; Oxford University Clinical Research Unit, Vietnam; National Hospital of Pediatrics, Vietnam
Recruiting - verified April 2012 - Conditions: HIV; Tuberculosis; Pediatric
Intervention: Other: Development of a diagnosis algorithm
Sponsors: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS); French National Agency for Research on AIDS and Viral Hepatitis; Pasteur Institute in Cambodia; National Pediatric Hospital, Cambodia; Angkor Hospital for Children; Pham Ngoc Thach Hospital, Vietnam; Pediatric Hospital Nhi Dong 1, Ho Chi Minh City, Vietnam; Pediatric Hospital Nhi Dong 2, Ho Chi Minh City, Vietnam; Hôpital Necker-Enfants Malades; Groupe Hospitalier Pitie-Salpetriere; CHRU Arnaud de Villeveuve, Montpellier, France; IRD, Yaounde, Cameroon; Fondation Chantal Biya,Yaounde, Cameroon; CHU Sourô Sanou, Bobo Dioulasso, Burkina Faso
Recruiting - verified May 2012 - Condition: Bacterial Conjunctivitis
Interventions: Drug: Besivance; Drug: Gatifloxacin
Sponsors: Bausch & Lomb, Inc.; Bausch & Lomb, Inc.
Recruiting - verified January 2012 - Conditions: SIRS; Sepsis; Severe Sepsis; Septic Shock
Intervention:
Sponsors: Groupe Hospitalier Paris Saint Joseph; Groupe Hospitalier Paris Saint Joseph; Biomerieux; Institut Pasteur; Assistance Publique - Hôpitaux de Paris
Recruiting - verified October 2011 - Conditions: HIV; Hepatitis C; Hepatitis B; Syphilis
Interventions: Device: Rapid tests for HIV, HCV, HBV, and syphilis; Device: HIV/HCV; Device: HIV/syphilis; Device: HIV only
Sponsors: California State University, Long Beach; California State University, Long Beach; National Institute on Drug Abuse (NIDA)
Recruiting - verified February 2012 - Conditions: Q Fever; Fatigue Syndrome, Chronic; Coxiella Infection
Interventions: Behavioral: Cognitive behavioral therapy; Drug: Doxycycline; Drug: Placebo
Sponsors: Radboud University; Radboud University; ZonMw: The Netherlands Organisation for Health Research and Development
Recruiting - verified April 2011 - Conditions: Abscess; Wound Infection; Surgical Site Infection; Cellulitis
Interventions: Drug: Dalbavancin; Drug: Vancomycin
Sponsors: Durata Therapeutics, Inc.; Durata Therapeutics, Inc.
Recruiting - verified March 2012 - Condition: Cystic Fibrosis
Intervention: Drug: Liposomal amikacin for inhalation
Sponsors: Insmed; Insmed
Not yet recruiting - verified March 2012 - Condition: Cystic Fibrosis
Interventions: Drug: Liposomal amikacin for inhalation; Drug: Tobramycin inhalation solution
Sponsors: Insmed; Insmed
Recruiting - verified March 2012 - Conditions: HIV; Hepatitis C; Syphilis; Herpes Simplex Type II
Interventions: Behavioral: MMT provider dosage training; Behavioral: targeted counseling; Other: national guidelines
Sponsors: Centers for Disease Control and Prevention; Centers for Disease Control and Prevention; National Center for AIDS/STD Control and Prevention, China CDC
Recruiting - verified April 2012 - Condition: Tuberculosis
Intervention: Drug: Moxifloxacin
Sponsors: University Medical Centre Groningen; University Medical Centre Groningen
Recruiting - verified May 2011 - Condition: Phthisis Bulbi
Interventions: Device: 3DP; Device: Medpor
Sponsors: Mettapracharak Hospital; Mettapracharak Hospital; Thailand Research Fund; Prince of Songkla University
Recruiting - verified May 2012 - Conditions: Bacterial Infection; Mucositis; Neutropenia
Interventions: Drug: supersaturated calcium phosphate rinse; Other: placebo
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Pneumococcal Infection
Intervention: Biological: PNEUMOVAX
Sponsors: Emory University; Emory University; National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified April 2012 - Condition: Drug Safety
Interventions: Drug: Ertapenem; Drug: Meropenem or Imipenem
Sponsors: Mahidol University; Mahidol University
Recruiting - verified December 2011 - Conditions: Tuberculosis; Urea Breath Test
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified December 2011 - Condition: Atypical; Mycobacterium, Pulmonary, Tuberculous
Interventions: Drug: Clarithromycin; Drug: Moxifloxacin
Sponsors: Centre Hospitalier Universitaire, Amiens; Centre Hospitalier Universitaire, Amiens
Recruiting - verified February 2012 - Conditions: Antibiotic Associated Diarrhea; Clostridium Difficile Infection; Gastroenteritis
Intervention: Dietary Supplement: L reuteri in children on antibiotics
Sponsors: St Marina University Hospital, Varna, Bulgaria; St Marina University Hospital, Varna, Bulgaria
Recruiting - verified October 2011 - Condition: Meningococcal Disease
Intervention:
Sponsors: London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Bill and Melinda Gates Foundation
Recruiting - verified April 2012 - Conditions: Chlamydia Infection; Gonococcal Infection; Sexually Transmitted Diseases
Intervention:
Sponsors: University of California, San Francisco; University of California, San Francisco; Abbott Molecular
Not yet recruiting - verified April 2012 - Condition: Tuberculosis
Interventions: Dietary Supplement: Placebo; Dietary Supplement: Vitamin D3 (cholecalciferol)
Sponsors: University of California, San Diego; University of California, San Diego; Thrasher Research Fund
Recruiting - verified July 2011 - Condition: Bacteremia
Intervention: Drug: Vancomycin vs. daptomycin
Sponsors: St. John Health System, Michigan; St. John Health System, Michigan; Henry Ford Health System; Cubist Pharmaceuticals
Recruiting - verified January 2011 - Condition: Ventilator-associated Bacterial Pneumonia
Interventions: Drug: Colistin; Drug: Meropenem
Sponsors: Spanish Clinical Research Network - CAIBER; Spanish Clinical Research Network - CAIBER; European Commission
Recruiting - verified April 2012 - Conditions: Primary Immune Deficiency Disorders; Common Variable Immunodeficiency; X-linked Agammaglobulinemia; Hyper-IgM Syndrome; Wiskott-Aldrich Syndrome
Intervention: Biological: Gammaplex
Sponsors: Bio Products Laboratory; Bio Products Laboratory
Recruiting - verified February 2012 - Condition: Clostridium Difficile Infection
Intervention: Biological: IC84
Sponsors: Intercell AG; Intercell AG
Recruiting - verified March 2012 - Conditions: Obsessive-Complusive Disorder; Children; Anxiety Disorder; Autoimmune Disease; PANDAS
Interventions: Drug: Gamunex Intravenous Immunoglobulin; Drug: Placebo
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Mental Health (NIMH)
Recruiting - verified October 2011 - Conditions: Vaginal Candidiasis; Bacterial Vaginosis; Trichomonal Vaginitis
Intervention: Drug: Metronidazole/Miconazole (Neo-Penotran® Forte, BAY86-5276)
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Conditions: Persistent Cough; Whooping Cough
Interventions: Drug: Montelukast; Drug: Placebo
Sponsors: University of Oxford; University of Oxford
Recruiting - verified November 2011 - Condition: Severe Sepsis
Intervention: Device: S.A.F.E.BT
Sponsors: B. Braun Medical Inc.; B. Braun Medical Inc.
Recruiting - verified February 2012 - Condition: Invasive Meningococcal Disease
Intervention: Biological: Meningococcal ABCWY vaccine
Sponsors: Novartis; Novartis
Recruiting - verified May 2012 - Conditions: Meningitis; Meningococcal Disease
Interventions: Biological: Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate; Biological: Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate; Biological: Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified January 2012 - Condition: Active Tuberculosis
Intervention:
Sponsors: Yonsei University; Yonsei University
Recruiting - verified August 2011 - Conditions: Idiopathic Bronchiectasis; Nontuberculous Mycobacterium (NTM) Infection
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified September 2011 - Condition: Tuberculosis
Interventions: Biological: GSK's investigational vaccine 692342; Biological: Physiological saline
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified January 2012 - Condition: Clostridium Difficile Infection
Interventions: Biological: VP20621; Biological: VP20621; Other: Placebo; Biological: VP20621
Sponsors: ViroPharma; ViroPharma
Recruiting - verified May 2012 - Condition: Helicobacter Pylori Infection
Interventions: Drug: high dose dual therapy; Drug: concomitant therapy
Sponsors: National Taiwan University Hospital; National Taiwan University Hospital; National Science Council, Taiwan
Recruiting - verified April 2012 - Conditions: Bacterial Infection; Postoperative Infection; Abdominal Infection
Interventions: Other: CD64 and Procalcitonin; Other: CD64 and Procalcitonin
Sponsors: University Hospital, Akershus; University Hospital, Akershus
Recruiting - verified July 2011 - Conditions: Pneumococcal Disease; Haemophilus Influenzae Infections
Interventions: Biological: Pneumococcal vaccine GSK2189242A (formulation 1); Other: Pneumococcal vaccine GSK2189242A (formulation 2); Biological: SynflorixTM; Biological: Prevenar 13TM; Biological: TritanrixTM-HepB/Hib; Biological: Polio SabinTM; Biological: M-VacTM; Biological: StamarilTM
Sponsors: GlaxoSmithKline; GlaxoSmithKline; Program for Appropriate Technology in Health; Department of State for Health and Social Welfare, The Gambia; Medical Research Council Laboratories, Gambia; London School of Hygiene and Tropical Medicine
Recruiting - verified December 2011 - Condition: Extrapulmonary Tuberculosis
Interventions: Genetic: Genetic analysis; Radiation: Body scan (CRANIO CERVICO THORACO ABDOMINAL); Other: Immunologic analysis; Other: QuantiferonTB Gold test
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris
Recruiting - verified June 2011 - Conditions: Bacterial Infection; Anti-infective Agents; Breast Implantation
Interventions: Drug: Cefadroxil discontinued early; Drug: Cefadroxil until drain removal
Sponsors: Stony Brook University; Stony Brook University; Plastic Surgery Educational Foundation
Recruiting - verified March 2012 - Conditions: Stevens-Johnson Syndrome; Corneal Blindness
Intervention: Drug: Infliximab
Sponsors: Massachusetts Eye and Ear Infirmary; Massachusetts Eye and Ear Infirmary; Massachusetts Eye Research and Surgery Institution
Recruiting - verified October 2011 - Conditions: Sarcoidosis; Tuberculosis
Intervention: Drug: Antituberculous therapy along with steroids
Sponsors: Postgraduate Institute of Medical Education and Research; Postgraduate Institute of Medical Education and Research
Recruiting - verified June 2011 - Condition: Clostridium Difficile Infection
Interventions: Biological: MK-3415; Biological: MK-6072; Biological: MK-3415A; Biological: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: H. Pylori Infection
Interventions: Device: Electrochemical H. pylori detection method; Device: IHC; Device: C13-urea breath test; Device: HUT
Sponsors: University of Erlangen-Nürnberg Medical School; University of Erlangen-Nürnberg Medical School
Recruiting - verified August 2011 - Condition: Moderate Clostridium Difficile Infection
Interventions: Drug: LFF571 (cohort 1); Drug: Vancomycin (cohort 1); Drug: LFF571 (cohort 2); Drug: LFF571 (cohort 2); Drug: LFF571; Drug: LFF571
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Clostridium Difficile Infection; Diarrhea
Interventions: Biological: Clostridium difficile toxoids A and B (Low-dose with adjuvant); Biological: Clostridium difficile toxoids A and B (Low-dose without adjuvant); Biological: Clostridium difficile toxoids A and B (high-dose with adjuvant); Biological: Clostridium difficile toxoids A and B (high-dose without adjuvant); Biological: Placebo: 0.9% normal saline
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Conditions: Wound Infection; Abscess; Systemic Inflammation; Cellulitis
Interventions: Drug: Single-Dose IV Oritavancin Diphosphate; Drug: IV Vancomycin
Sponsors: The Medicines Company; The Medicines Company
Recruiting - verified February 2012 - Conditions: Wound Infection; Abscess; Systemic Inflammation; Cellulitis
Interventions: Drug: Single-Dose IV Oritavancin Diphosphate; Drug: IV Vancomycin
Sponsors: The Medicines Company; The Medicines Company
Recruiting - verified February 2012 - Conditions: Bacterial Vaginosis; Candidiasis; Trichomoniasis
Interventions: Drug: Placebo; Drug: Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012 - Condition: Latent Tuberculosis Infection
Interventions: Drug: Preventive treatment with Isoniazid.; Drug: Preventive treatment with Isoniazid
Sponsors: Hospital Universitari de Bellvitge; Hospital Universitari de Bellvitge; Cellestis
Recruiting - verified May 2011 - Conditions: Cholera; Diarrhoea; Vibrio Infection
Interventions: Biological: Modified killed oral cholera vaccine at 14 day interval; Biological: Modified killed oral cholera vaccine at 28 day interval
Sponsors: International Vaccine Institute; International Vaccine Institute; National Institute of Cholera and Enteric Diseases, India; Indian Council of Medical Research; Shantha Biotechnics Limited
Recruiting - verified March 2012 - Condition: Clostridium Difficile Infection
Interventions: Drug: ACT-179811; Drug: Comparator
Sponsors: Actelion; Actelion
Recruiting - verified January 2012 - Conditions: HIV; Respiratory Infections; Fungal Pneumonia; Viral Pneumonia; Mycobacteria
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID); National Institutes of Health Clinical Center (CC)
Recruiting - verified July 2011 - Conditions: Diabetic Foot; Staphylococcus Aureus
Intervention: Biological: Genetic profiling of bacterial cultures
Sponsors: Centre Hospitalier Universitaire de Nīmes; Centre Hospitalier Universitaire de Nīmes; Institut National de la Santé Et de la Recherche Médicale, France
Recruiting - verified February 2012 - Condition: Tuberculosis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2011 - Conditions: Trachoma; Chlamydia
Intervention: Drug: mass treatment with oral azithromycin
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified April 2012 - Conditions: Bladder Neoplasm; Intravesical Drug Administration; Neoplasm Recurrence, Local; Transitional Cell, Carcinoma; Carcinoma in Situ; Mycobacterium
Intervention: Biological: EN3348
Sponsors: Endo Pharmaceuticals; Endo Pharmaceuticals
Recruiting - verified February 2012 - Condition: Tuberculosis
Intervention: Biological: AERAS-402
Sponsors: Aeras Global TB Vaccine Foundation; Aeras Global TB Vaccine Foundation; European and Developing Countries Clinical Trials Partnership (EDCTP)
Recruiting - verified January 2012 - Condition: Meningococcal Meningitis
Interventions: Biological: Menveo; Biological: MenACWY-TT conjugate vaccine
Sponsors: Health Protection Agency, United Kingdom; Health Protection Agency, United Kingdom
Not yet recruiting - verified March 2012 - Condition: Tuberculosis
Interventions: Biological: BCG: 100 microlitres ~ 2-8 x 105 pfu; Biological: MVA85A: 1 x 108 pfu BCG: 100 microlitres ~ 2-8 x 105 pfu
Sponsors: University of Oxford; University of Oxford
Recruiting - verified October 2011 - Condition: Bacteremia
Interventions: Drug: Vancomycin; Drug: Vancomycin
Sponsors: Duke University; Duke University; National Institutes of Health (NIH)
Recruiting - verified February 2012 - Condition: Bacteremia
Interventions: Drug: Ethanol-lock therapy; Drug: Antibiotic-lock
Sponsors: IRCCS Policlinico S. Matteo; IRCCS Policlinico S. Matteo
Recruiting - verified January 2012 - Conditions: Rheumatic Heart Disease; Congenital Heart Disease; Aneurysm; Heart Valve Disease
Intervention: Drug: Simvastatin
Sponsors: Sun Yat-sen University; Sun Yat-sen University
Recruiting - verified September 2010 - Condition: Bacteremia
Intervention:
Sponsors: Meir Medical Center; Meir Medical Center
Recruiting - verified March 2012 - Condition: Helicobacter Pylori Infection
Interventions: Drug: Molecular detection of antibiotic resistance; Drug: standard triple therapy (PPI, amoxicillin, clarithromycin, metronidazole)
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris
Recruiting - verified May 2011 - Condition: Tuberculosis
Intervention:
Sponsors: Meir Medical Center; Meir Medical Center
Recruiting - verified March 2012 - Conditions: Obesity; Pharmacokinetics; MRSA; Tuberculosis; PCP
Intervention: Drug: Sulfamethoxazole/trimethoprim
Sponsors: Texas Tech University Health Sciences Center; Texas Tech University Health Sciences Center; National Center for Research Resources (NCRR); University of Texas Southwestern Medical Center
Recruiting - verified February 2012 - Conditions: Obesity; Leprosy; Tuberculosis
Intervention: Drug: Dapsone
Sponsors: Texas Tech University Health Sciences Center; Texas Tech University Health Sciences Center; National Center for Research Resources (NCRR)
Recruiting - verified February 2012 - Conditions: Meningitis, Tuberculous; Pharmacokinetics; Pharmacodynamics; Tolerability
Intervention: Drug: Moxifloxacin
Sponsors: Universitas Padjadjaran; Universitas Padjadjaran; Radboud University
Recruiting - verified December 2011 - Condition: Helicobacter Infection
Interventions: Drug: high dose dual therapy; Drug: sequential therapy; Drug: clarithromycin-based triple therapy; Drug: levofloxacin-based triple therapy
Sponsors: National Taiwan University Hospital; National Taiwan University Hospital; National Science Council, Taiwan
Recruiting - verified March 2012 - Condition: Pulmonary Tuberculosis
Intervention: Drug: Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol
Sponsors: Tuberculosis Research Centre, India; Tuberculosis Research Centre, India; National Institutes of Health (NIH)
Recruiting - verified June 2011 - Condition: Pulmonary Nontuberculous Mycobaterium Infection
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institutes of Health Clinical Center (CC)
Recruiting - verified March 2012 - Conditions: Tuberculosis; HIV Infections
Interventions: Biological: MVA85A/AERAS-485; Biological: Candida albicans Skin Test Antigen
Sponsors: Aeras Global TB Vaccine Foundation; Aeras Global TB Vaccine Foundation; University of Oxford; European and Developing Countries Clinical Trials Partnership (EDCTP)
Recruiting - verified August 2011 - Condition: Chlamydia
Interventions: Drug: ceftriaxone; Drug: Azithromycin
Sponsors: University of Pittsburgh; Thomas L. Cherpes, MD; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012 - Condition: Colchicine Resistant/Intolerant Familial Mediterranean Fever
Intervention: Drug: Canakinumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Meningococcal Meningitis
Interventions: Biological: Meningococcal ACWY conjugate vaccine; Biological: Meningococcal ACWY conjugate vaccine
Sponsors: Novartis; Novartis Vaccines
Recruiting - verified May 2012 - Conditions: Lyme Disease; Borrelia Burgdorferi
Interventions: Procedure: Skin Biopsy; Device: Xenodiagnosis; Procedure: Blood Drawing
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012 - Condition: Methicillin-resistant Staphylococcus Aureus
Intervention:
Sponsors: Boston Medical Center; Boston Medical Center
Recruiting - verified July 2011 - Condition: Necrotizing Fasciitis
Intervention:
Sponsors: National Taiwan University Hospital; National Taiwan University Hospital
Recruiting - verified June 2011 - Conditions: Staphylococcal Infections; Methicillin-resistant Staphylococcus Aureus
Interventions: Drug: Daptomycin; Drug: Vancomycin
Sponsors: Mountain Home Research & Education Corporation; Mountain Home Research & Education Corporation; East Tennessee State University; Cubist Pharmaceuticals
Recruiting - verified August 2011 - Conditions: Diphtheria; Tetanus; Pertussis
Intervention: Biological: ADACEL™:Adsorbed Diphtheria, Tetanus Toxoids and Component Pertussis Combined
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified March 2012 - Condition: Rickettsioses
Intervention:
Sponsors: Kaohsiung Medical University Chung-Ho Memorial Hospital; Kaohsiung Medical University Chung-Ho Memorial Hospital
Recruiting - verified June 2011 - Condition: Septicemia
Interventions: Biological: CPG 7909; Biological: J5-OMP Vaccine; Drug: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011 - Condition: Sinusitis
Interventions: Drug: Amoxicillin-Potassium Clavulanate Combination; Drug: Placebo
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison; Thrasher Research Fund
Recruiting - verified December 2011 - Condition: Invasive Meningococcal Disease
Interventions: Biological: Glyco-conjugate Neisseria meningitidis serogroup C (MenC) vaccine; Biological: Routine schedule immunisations except monovalent MenC vaccine
Sponsors: University of Oxford; University of Oxford; Oxford University Hospitals NHS Trust; GlaxoSmithKline
Recruiting - verified July 2011 - Condition: Pertussis
Interventions: Biological: Pentacel® (DTaP-IPV/Hib); Biological: Other Pertussis Vaccines
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Helicobacter Infections
Intervention: Drug: Rabeprazole, metronidazole, Clarithromycin, Amoxicillin
Sponsors: American University of Beirut Medical Center; American University of Beirut Medical Center
Recruiting - verified January 2012 - Condition: Treatment Duration for Abdominal Tuberculosis
Interventions: Drug: RNTCP Category I treatment for 6 months; Drug: RNTCP Category I treatment for 9months
Sponsors: All India Institute of Medical Sciences, New Delhi; All India Institute of Medical Sciences, New Delhi; Sanjay Gandhi Postgraduate Institute of Medical Sciences; Christian Medical College, Vellore, India
Recruiting - verified December 2011 - Condition: Bacterial Infections
Interventions: Dietary Supplement: fortification with iron and micronutrients; Dietary Supplement: Sprinkles
Sponsors: Swiss Federal Institute of Technology; Swiss Federal Institute of Technology; University of KwaZulu; University of Nairobi
Recruiting - verified April 2012 - Conditions: Cross Infection; Bacteriuria
Interventions: Dietary Supplement: cranberry type A pro anthocyandines; Dietary Supplement: Placebo
Sponsors: Centre Hospitalier Universitaire de Nīmes; Centre Hospitalier Universitaire de Nīmes
Recruiting - verified February 2012 - Condition: Helicobacter Pylori Infection
Intervention: Drug: GT08
Sponsors: Synergy Pharmaceuticals Pte. Ltd.; Synergy Pharmaceuticals Pte. Ltd.; Singapore General Hospital
Recruiting - verified May 2011 - Conditions: Impetigo; Folliculitis; Secondarily Infected Eczema; Minor Soft Tissue Infections
Intervention: Drug: Retapamulin (Altabax)
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston; GlaxoSmithKline
Recruiting - verified February 2012 - Condition: Vesicoureteral Reflux
Intervention:
Sponsors: Children's Research Institute; Children's Research Institute
Not yet recruiting - verified April 2012 - Conditions: Staphylococcus Aureus; Community-associated MRSA Infections; Staphylococcal Skin Infections
Interventions: Drug: Chlorhexidine gluconate; Other: Standardized training and education
Sponsors: Uniformed Services University of the Health Sciences; Uniformed Services University of the Health Sciences; Centers for Disease Control and Prevention
Recruiting - verified July 2011 - Conditions: Complicated Skin and Skin Structure Infections; S. Aureus Bacteremia; Renal Impairment
Interventions: Drug: Vancomycin; Drug: Vancomycin; Drug: Daptomycin 7-14 days moderate renal impairment; Drug: Daptomycin 7 - 14 days severe renal impairment, hemodialysis; Drug: Daptomycin 7 - 14 days severe renal impairment no hemodialysis; Drug: Daptomycin 14 - 42 days, moderate renal impairment; Drug: Daptomycin 14 - 42 days, severe renal impairment on hemodialysis; Drug: Daptomycin 14 - 42 days severe renal impairment, no hemodialysis
Sponsors: Cubist Pharmaceuticals; Cubist Pharmaceuticals
Recruiting - verified September 2011 - Condition: Kidney Transplant Recipient
Intervention: Drug: Isoniazid treatment
Sponsors: Asan Medical Center; Asan Medical Center
Recruiting - verified February 2012 - Conditions: Peritonitis; Catheter-related Infections; Renal Insufficiency
Interventions: Device: Taurolock; Other: Placebo
Sponsors: Centre Hospitalier Universitaire de Nīmes; Centre Hospitalier Universitaire de Nīmes
Recruiting - verified February 2012 - Condition: Pertussis
Intervention:
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified March 2012 - Conditions: Tuberculosis; Tuberculosis, Multidrug-Resistant; Extensively Drug Resistant Tuberculosis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2011 - Condition: Erysipelas
Interventions: Drug: Amoxicillin; Drug: Amoxicillin
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris; Ministry of Health, France; French Dermatology Society
Not yet recruiting - verified January 2010 - Condition: Treatment of Early Pulmonary Infections With P. Aeruginosa in Cystic Fibrosis Patients
Interventions: Drug: TOBI; Drug: Placebo to TOBI
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: H. Pylori Infection
Interventions: Drug: Sequential therapy for 14 days; Drug: Sequential therapy for 10 days; Drug: Triple therapy for 14 days
Sponsors: National Taiwan University Hospital; National Taiwan University Hospital
Recruiting - verified June 2011 - Condition: Helicobacter Pylori Infection
Intervention: Drug: susceptibility test guided sequential therapy
Sponsors: National Taiwan University Hospital; National Taiwan University Hospital
Recruiting - verified May 2011 - Conditions: Tick-Borne Encephalitis; Encephalitis, Tick-Borne; Tick-Borne Disease; Glycoprotein E, Flavivirus; NSI Protein, Flavivirus
Intervention: Biological: FSME-IMMUN 0.5ml Baxter
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified July 2011 - Condition: Gram Positive Bacterial Infection
Intervention: Drug: Daptomycin
Sponsors: Cubist Pharmaceuticals; Cubist Pharmaceuticals
Recruiting - verified January 2012 - Condition: Cardiac Rhythm Management Device Infection
Intervention:
Sponsors: TYRX, Inc.; TYRX, Inc.
Recruiting - verified July 2011 - Condition: Implantable Cardioverter-Defibrillator Infection
Intervention:
Sponsors: TYRX, Inc.; TYRX, Inc.
Recruiting - verified July 2011 - Condition: Tuberculosis
Intervention:
Sponsors: Asan Medical Center; Asan Medical Center
Recruiting - verified February 2012 - Conditions: Chronic Kidney Disease; Bacterial Infection
Intervention: Drug: Daptomycin
Sponsors: University of Oklahoma; University of Oklahoma; Cubist Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Anaplasmosis; Tick-borne Disease; Ehrlichia
Intervention: Procedure: Blood sampling
Sponsors: University Hospital, Strasbourg, France; University Hospital, Strasbourg, France
Recruiting - verified August 2011 - Condition: Urinary Tract Infections
Interventions: Drug: Diclofenac; Drug: Norfloxacin
Sponsors: University Hospital Inselspital, Berne; University Hospital Inselspital, Berne; Institute for Infectious Diseases, University of Berne, Switzerland; CTU Bern, Bern University Hospital, and Institute of Social and Preventive Medicine, University of Bern, Switzerland; Clinic for Infectious Diseases, University Hospital Bern, Switzerland; University of Bern
Not yet recruiting - verified November 2011 - Condition: C. Trachomatis
Interventions: Drug: Azithromycin; Drug: Doxycycline
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Condition: Staphylococcus Enterotoxin B
Intervention: Biological: STEBVax
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified February 2012 - Conditions: HIV Infections; Pneumococcal Infections
Interventions: Biological: 13-valent Pneumococcal Conjugate Vaccine (13vPnC); Biological: 23-valent Pneumococcal Polysaccharide Vaccine (23vPS); Procedure: Blood draw; Procedure: Blood draw
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Conditions: Bacterial Infections; Wounds
Interventions: Drug: Vancomycin 1.25-1.50% in a complex calcium alginate gel formulation; Drug: Vancomycin 1.25-1.5% compounded with a complex calcium alginate gel
Sponsors: Robert S Berman MD; Robert S Berman MD
Recruiting - verified November 2011 - Conditions: HIV Infection; Pulmonary TB
Intervention: Drug: ATT (Ethambutol, Pyrazinamide, INH, Rifampicin)
Sponsors: Tuberculosis Research Centre, India; Tuberculosis Research Centre, India
Recruiting - verified October 2011 - Condition: Latent Tuberculosis Infection
Interventions: Drug: Isoniazid; Drug: Rifampin
Sponsors: McGill University; McGill University; Canadian Institutes of Health Research (CIHR)
Recruiting - verified June 2011 - Condition: Gonococcal Infections
Interventions: Drug: Azithromycin; Drug: Gentamicin; Drug: Gemifloxacin
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011 - Condition: Tuberculosis
Interventions: Dietary Supplement: Vitamin D pill; Dietary Supplement: Placebo
Sponsors: Emory University; Emory University
Recruiting - verified June 2011 - Conditions: Staphylococcal Aureus Infection; Recurrent Staphylococcal Infection; Invasive Staphylococcal Infection
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2012 - Condition: Nervous System Lyme Borreliosis
Intervention: Drug: ceftriaxone
Sponsors: University Medical Centre Ljubljana; University Medical Centre Ljubljana
Recruiting - verified October 2011 - Condition: Latent Tuberculosis Infection
Intervention:
Sponsors: Germans Trias i Pujol Hospital; Germans Trias i Pujol Hospital; Fondo de Investigacion Sanitaria
Recruiting - verified November 2009 - Condition: Tuberculosis
Intervention:
Sponsors: Germans Trias i Pujol Hospital; Germans Trias i Pujol Hospital; CIBERES CRP-TB program
Recruiting - verified November 2009 - Condition: Meningitis, Meningococcal
Interventions: Biological: rLP2086 vaccine or control; Biological: rLP2086 vaccine or control; Biological: rLP2086 vaccine or control; Biological: rLP2086 vaccine or control
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Pulmonary Tuberculosis
Intervention: Drug: Moxifloxacin,Ethambutol,Isoniazid,Pyrazinamide & Rifampicin
Sponsors: University College, London; University College, London; European and Developing Countries Clinical Trials Partnership (EDCTP); Global Alliance for TB Drug Development; Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma; Sanofi-Aventis; Svizera Labs, Almere, Netherlands
Recruiting - verified January 2012 - Condition: Tuberculosis
Interventions: Drug: Albendazole; Drug: Placebo
Sponsors: Linkoeping University; Linkoeping University; University of Gondar; Armauer Hansen Research Institute, Ethiopia
Recruiting - verified February 2012 - Conditions: Haemophilus Infections; Diphtheria; Tetanus; Polio; Pertussis
Intervention: Biological: DTaP-IPV/Hib
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified January 2012 - Condition: Meningococcal Meningitis
Interventions: Other: Blood draw; Other: Blood draw; Other: Blood draw; Biological: Group IV; Biological: Group V
Sponsors: Novartis; Novartis Vaccines
Recruiting - verified May 2012 - Condition: Leprosy
Intervention: Drug: clofazamine
Sponsors: Kaiser Permanente; Kaiser Permanente; National Hansen's Disease Program
Available - verified April 2012 - Conditions: Bacterial Infections; Bacteremia; Gram-Positive Bacterial Infections; Inflammation
Intervention:
Sponsors: Odense University Hospital; Odense University Hospital
Recruiting - verified October 2011 - Condition: Tuberculosis
Interventions: Drug: RIF; Drug: INH; Drug: PZA; Drug: KM; Drug: MXF
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID); Korean Center for Disease Control and Prevention; International Tuberculosis Research Center; Novartis Institute for Tropical Medicine; Asian Medical Center
Recruiting - verified August 2011 - Condition: Tuberculosis
Interventions: Drug: Rifapentine; Drug: Rifapentine; Drug: Rifampin
Sponsors: Johns Hopkins University; Johns Hopkins University; University of Cape Town Lung Institute; University of Cape Town; FDA Office of Orphan Products Development
Recruiting - verified February 2012 - Condition: Tuberculous Pericarditis
Interventions: Drug: Prednisolone; Biological: Mycobacterium w immunotherapy
Sponsors: University of Cape Town; University of Cape Town; Population Health Research Institute
Recruiting - verified January 2012 - Condition: Pneumonia, Bacterial
Interventions: Drug: Amikacin Inhalation Solution (BAY41-6551); Drug: Aerosolized Placebo
Sponsors: Bayer; Bayer
Not yet recruiting - verified April 2012 - Conditions: Diphtheria; Tetanus; Pertussis; Haemophilus Influenzae
Interventions: Biological: DTaP-IPV/Hib; Biological: Other DTap Vaccines
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012 - Conditions: HIV Infections; Tuberculosis
Interventions: Drug: Efavirenz (EFV); Drug: Rifampin-containing anti-TB therapy
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified April 2012 - Condition: Tuberculosis
Interventions: Biological: Ad5Ag85A; Biological: Ad5Ag85A
Sponsors: McMaster University; McMaster University
Recruiting - verified October 2011 - Condition: Bacterial Vaginosis
Interventions: Drug: Gelatin; Drug: Boric acid; Drug: Metronidazole
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified April 2012 - Condition: Tularemia
Intervention: Biological: Live Francisella Tularensis Vaccine
Sponsors: U.S. Army Medical Research and Materiel Command; U.S. Army Medical Research and Materiel Command
Recruiting - verified May 2012 - Condition: Meningococcal Infections
Intervention: Biological: NZ MenB OMV vaccine (NZ98/254)
Sponsors: United Bristol Healthcare NHS Trust; United Bristol Healthcare NHS Trust; University of Bristol; Health Protection Agency, United Kingdom; Novartis Vaccines; North Bristol NHS Trust
Recruiting - verified January 2010 - Condition: Acute Pharyngeal Tonsil
Interventions: Drug: Ketoprofen + amoxicillin; Drug: placebo + amoxicillin
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified December 2011 - Condition: Vibrio Cholerae
Intervention: Biological: killed bivalent (O1 and O139)whole cell oral cholera vaccine
Sponsors: International Vaccine Institute; International Vaccine Institute; Shantha Biotechnics Limited; Christian Medical College, Vellore, India
Recruiting - verified March 2012 - Conditions: Poliomyelitis; Haemophilus Influenzae Type b Disease; Hepatitis B; Diphtheria; Pertussis; Tetanus
Intervention: Biological: Infanrix™ hexa
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified August 2011 - Condition: Bacterial Vaginosis
Interventions: Other: Probiotic lactobacilli; Other: Placebo
Sponsors: University Ghent; University Ghent; IWT, Belgium
Recruiting - verified February 2012 - Conditions: HIV; AIDS; Tuberculosis
Interventions: Drug: Simultaneous ARV and antiMTB; Drug: Deferred RV and antiMTB treatment
Sponsors: Instituto Nacional de Enfermedades Respiratorias; Instituto Nacional de Enfermedades Respiratorias; Consorcio de Investigación sobre VIH/SIDA/TB (CISIDAT).
Recruiting - verified August 2008 - Condition: Methicillin-Resistant S.Aureus
Interventions: Drug: Clindamycin; Drug: Placebo; Drug: Trimethoprim-sulfamethoxazole (TS)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2011 - Condition: Tuberculosis
Interventions: Drug: Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid; Drug: Isoniazid, Rifampin, Pyrazinamide, Ethambutol
Sponsors: Johns Hopkins University; Johns Hopkins University; Federal University of Rio de Janeiro; Municipal Health Secretary of Rio de Janeiro; Helio Fraga Reference Center, Fiocruz
Recruiting - verified February 2012 - Condition: Pulmonary Tuberculosis
Interventions: Drug: rifampin; Drug: rifapentine; Drug: rifapentine; Drug: rifapentine
Sponsors: Centers for Disease Control and Prevention; Centers for Disease Control and Prevention; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Leprosy
Interventions: Drug: Rifampicin and Dapsone; Drug: Rifampicin, Clofazimine and Dapsone; Drug: Rifampicin, Clofazimine and Dapsone; Drug: Rifampicin, Clofazimine and Dapsone
Sponsors: University of Brasilia; University of Brasilia; Conselho Nacional de Desenvolvimento Científico e Tecnológico; Ministério de Ciência e Tecnologia; Ministério da Saúde
Recruiting - verified August 2011 - Condition: Bacterial Vaginosis
Interventions: Other: No Intervention; Drug: Metronidazole
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011 - Conditions: HIV Infections; Tuberculosis
Interventions: Drug: rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 1; Drug: rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 2
Sponsors: French National Agency for Research on AIDS and Viral Hepatitis; French National Agency for Research on AIDS and Viral Hepatitis
Recruiting - verified October 2011 - Condition: Pregnant Women
Interventions: Drug: Clindamycin; Drug: Placebo; Drug: Clindamycin
Sponsors: University Hospital, Lille; University Hospital, Lille; Pfizer
Recruiting - verified January 2008 - Condition: Lyme Borreliosis
Intervention: Other: Cutaneous biopsy
Sponsors: University Hospital, Strasbourg, France; University Hospital, Strasbourg, France; Société Française de Dermatologie
Recruiting - verified March 2012 - Conditions: Cholera; Diarrhea; Vibrio Infections
Interventions: Biological: Bivalent killed oral cholera vaccine; Biological: Killed Escherichia coli K12 placebo
Sponsors: International Vaccine Institute; International Vaccine Institute; Indian Council of Medical Research; National Institute of Cholera and Enteric Diseases, India; Shantha Biotechnics Limited; Institute of Child Health
Not yet recruiting - verified March 2012 - Condition: Urinary Tract Infection
Intervention: Other: E. coli 83972 coated urinary catheter
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Not yet recruiting - verified November 2011 - Conditions: HIV Infections; Tuberculosis
Interventions: Drug: Antiretroviral medications; Drug: Antiretroviral medications+Isoniazid prophylaxis; Drug: Antiretroviral medications; Drug: Antiretroviral medications+Isoniazid prophylaxis
Sponsors: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS); French National Agency for Research on AIDS and Viral Hepatitis; Gilead Sciences; Merck
Recruiting - verified March 2012 - Conditions: Mycobacterium Infections, Atypical; Granulomatous Disease, Chronic; Job's Syndrome; Influenza, Human
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified September 2011 - Conditions: Staphylococcal Infections; Meningitis; Sepsis; Pneumonia
Interventions: Drug: Cotrimoxazole; Drug: Vancomycin
Sponsors: Rabin Medical Center; Rabin Medical Center
Recruiting - verified October 2011 - Conditions: Prosthesis-related Infections; Staphylococcal Infections
Interventions: Drug: Rifampin-combination therapy; Drug: Monotherapy
Sponsors: Oslo University Hospital; Oslo University Hospital
Recruiting - verified March 2012 - Conditions: Mycobacteria, Atypical; Cystic Fibrosis; Ciliary Disorders; Pseudohypoaldosteronism; Bronchiectasis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2011 - Conditions: Bacterial Infection and Mycoses; Immunologic Disease; Inflammation; Parasitic Disease; Virus Disease
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011 - Conditions: Tuberculosis; Pulmonary Tuberculosis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID); International Tuberculosis Research Center; National Masan Tuberculosis Hospital; Korean Center for Disease Control and Prevention
Recruiting - verified January 2012 - Conditions: Tuberculosis; HIV
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified July 2011 - Condition: Bacteremia
Intervention: Other: No intervention
Sponsors: Duke University; Duke University; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2011 - Condition: Leprosy
Intervention:
Sponsors: Colorado State University; Colorado State University; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2010 - Conditions: Erythema Migrans Lesions; Erythema Migrans
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012 - Condition: Anthrax
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011 - Condition: Lyme Disease
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2011 - Conditions: Pseudomonas Infection; Cystic Fibrosis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified July 2011 - Conditions: Atypical Mycobacterium Infections; Cystic Fibrosis; Job's Syndrome
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011 - Conditions: Chronic Disease; Healthy; Lyme Arthritis; Lyme Disease; Multiple Sclerosis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011 - Condition: Periodic Disease
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified April 2012
 |
Join Clinical trials for Bacterial Infections |
